Astrazeneca plc

NASDAQ: AZN
$78.90
+$0.32 (+0.4%)
Closing Price on September 19, 2024

AZN Articles

Inovio Pharmaceuticals made waves early on Tuesday morning following an update for its human papillomavirus (HPV) treatment.
March 22, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Tuesday’s session. AstraZeneca PLC (NYSE: AZN) dropped about 2.5% on Tuesday...
Tuesday's top analyst initiations, upgrades and downgrades include AstraZeneca, 3D Systems, Barrick Gold, Home Depot, Oasis Petroleum and Whiting Petroleum.
AstraZeneca has announced that the European Commission granted marketing authorization for two of its treatments: Zurampic for gout and Brilique for heart attack patients.
The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.
Stocks tanked on Friday but were indicated sharply higher on Tuesday after the three-day weekend and after China’s gross domestic product met expectations. While investors may feel that every rally...
Good news for those who suffer from high levels of uric acid and from gout: the FDA has approved a new gout treatment.
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Wednesday's top analyst upgrades, downgrades and initiations include Aegerion Pharmaceuticals, Amazon.com, EMC, McDonald's, MetLife, Microsoft, SanDisk and Tyco International.
Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.
Monday's top analyst upgrades, downgrades and initiations include AeroVironment, Gold Fields, Marvell Technology, Nokia and Silver Wheaton.
Wednesday’s top analyst upgrades, downgrades and initiations include ARM Holdings, AT&T, Hasbro, Lending Club, PNC Financial Services, Vodafone and Walt Disney.
With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.
Teva Pharmaceutical announced on Monday that the FDA approved the first generic equivalent to Nexium delayed-release capsules in the United States.